Petri H, Rudolph W
Herz. 1979 Aug;4(4):344-58.
Guidelines for a step-wise plan of treatment of tachycardias have been compiled based on clinical empirical experience and with the aid of surface electrocardiograms, intracardial electrograms and stimulation techniques. The plan is primarily with the aid of surface electrocardiograms, intracardial electrograms and stimulation techniques. The plan is primarily oriented with respect to the antiarrhythmic efficacy, the adverse reactions and the practicability of the respective agents. Any type of tachycardia, including premature atrial or ventricular contractions, may be regarded as indication for treatment. Treatment is not indicated only in those asymptomatic patients with rare and evanescent tachycardias and in those with less than 300 premature contractions per hour. Beta-adrenergic blockers are the drugs of choice for the persistent sinus tachycardia. Should the latter agents be contraindicated, propafenon, amiodarone or aprindine may be administered. Verapamil and/or digitalis are indicated only for suppression of paroxysmal sinus tachycardias. Atrial premature contractions are best managed with guinidine or disopyramid. An acute reduction of rapid ventricular rates associated with atrial tachycardias, atrial flutter or fibrillation can best be attained through the administration of verapamil prior to digitalis or beta-adrenergic blockers. Re-establishment of sinus rhythm and prophylactic suppression of the latter should be undertaken with quinidine or disopyramid in combination with digitalis and/or either a beta-adrenergic blocker or intravenously-administered verapamil. Verapamil is the drug of choice for initial management of AV-junctional tachycardia for which a combination with digitalis may be considered. An alternative combination is that of a beta-adrenergic blocker and digitalis. For the acute treatment of ventricular tachycardias, lidocain has proved most effective. Although ajmaline and/or propafenon may be given should no response be obtained, electrical cardioversion would be more appropriate. To prevent ventricular tachycardia or when treatment is indicated for ventricular premature beats, ajmaline, propafenon, quinidine, disopyramid or mexiletine, occasionally in combination with a beta-adrenergic blocker should be employed. Verapamil and/or ajmaline, are usually very effective for termination of reciprocal tachycardias. Ajmaline or propafenon in combination with a beta-adrenergic blocker is recommended for the prophylactic treatment of reciprocal tachycardia. In patients who additionally have bradycardia, prolonged QT-intervals or pre-excitation syndromes, the guidelines should be modified accordingly.
基于临床经验,并借助体表心电图、心内电图和刺激技术,已制定了一份心动过速逐步治疗计划指南。该计划主要借助体表心电图、心内电图和刺激技术。该计划主要根据各种药物的抗心律失常疗效、不良反应及实用性来制定。任何类型的心动过速,包括房性或室性早搏,都可视为治疗指征。仅在那些无症状、心动过速罕见且短暂,以及每小时早搏少于300次的患者中,不建议进行治疗。β-肾上腺素能阻滞剂是持续性窦性心动过速的首选药物。如果这些药物禁忌,可使用普罗帕酮、胺碘酮或阿普林定。维拉帕米和/或洋地黄仅用于抑制阵发性窦性心动过速。房性早搏最好用奎尼丁或丙吡胺治疗。与房性心动过速、心房扑动或心房颤动相关的快速心室率的急性降低,最好在使用洋地黄或β-肾上腺素能阻滞剂之前给予维拉帕米来实现。应使用奎尼丁或丙吡胺联合洋地黄和/或β-肾上腺素能阻滞剂或静脉注射维拉帕米来恢复窦性心律并进行预防性抑制。维拉帕米是房室交界性心动过速初始治疗的首选药物,可考虑联合洋地黄。另一种联合用药是β-肾上腺素能阻滞剂和洋地黄。对于室性心动过速的急性治疗,利多卡因已被证明最为有效。如果没有反应,虽然可给予阿马林和/或普罗帕酮,但电复律可能更合适。为预防室性心动过速或当需要治疗室性早搏时,应使用阿马林、普罗帕酮、奎尼丁、丙吡胺或美西律,偶尔联合β-肾上腺素能阻滞剂。维拉帕米和/或阿马林通常对终止折返性心动过速非常有效。建议使用阿马林或普罗帕酮联合β-肾上腺素能阻滞剂来预防性治疗折返性心动过速。对于另外有心动过缓、QT间期延长或预激综合征的患者,应相应修改指南。